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779Although a higher body mass index (BMI) is associated with a
proportionally increased risk of incident heart failure (HF) (1),
an elevated BMI in chronicHF is paradoxically associatedwith
improved prognosiswhen comparedwithpersonswith “normal
weight” (2–7). However, it is less clear whether adiposity
inﬂuences outcomes in the acuteHF setting. Although registry
studies suggest a 10% lower in-hospital mortality for every
5 kg/m2 increase in BMI, after adjustment for age, sex, renal,
and hemodynamic proﬁle (6), longer-term implications for
patients surviving to discharge remain underexplored.See page 786
LVEF = left ventricular
ejection fraction
NRI = net reclassiﬁcation
improvement
Within the context of this HF obesity paradox, it is unclear
how to reconcile general recommendations for ideal cardio-
vascular health (8), which articulate the importance of weight
loss to preserve cardiometabolic health. Mechanistically,
there is debate as to whether obesity itself may be protective
in HF (e.g., as a marker of improved nutrition, less tumor
necrosis factor-alpha activation and cachexia, or direct he-
modynamic inﬂuences), or whether a low BMI is confounded
by residual, unexplained factors that promote mortality (e.g.,
frailty). Although the obesity paradox itself has been docu-
mented in regional cohorts in different cardiovascular dis-
eases (9), deﬁning the role of adiposity in HF and addressing
which speciﬁc aspects of the patient with advanced cardiac
illness are important in modifying associations between BMI
and mortality in a global setting is critical.
In a prospective, observational, intercontinental cohort of
6,142 patients, we examined the relationship between BMI
and mortality after acute decompensated heart failure
(ADHF) hospitalization worldwide, independent of tradi-
tional markers of risk. We deﬁned speciﬁc factors in patients
with ADHF that may mediate these associations between
BMI and HF prognosis to clarify potential mechanisms of
beneﬁt (or harm) with adiposity. Ultimately, our overall goal
was to clarify the prognostic impact of obesity in ADHF and
to deﬁne subgroups within which adiposity may play a
prominent role in mediating adverse prognosis.
Methods
Study population and adjudication of clinical outcomes.
The study population was derived from a collection of 12
cohorts of patients with ADHF from 4 continents: Europe
(n ¼ 8; 2 in Italy, Austria, and the Czech Republic; 1 infrom Abbott Diagnostics, Brahms AG, and Roche Diagnostics. Dr. Pascual-Figal has
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accepted September 22, 2013.France, Finland, Switzerland, the
Netherlands, and Spain), North
America (n ¼ 2; United States),
Asia (n ¼ 1; Japan), and South
America (n ¼ 1; Argentina) (10–
19). The principal investigators
for each study submitted original
patient-level data from admis-
sion. All patients had a diagnosis
of ADHF on admission (regard-
less of new-onset HF or acute
decompensation of chronic HF),
according to clinical practice
guidelines (20). Clinical details
of presentation (medication use,
hemodynamics, comorbidities), as well as demographic,
echocardiographic, and biochemical data on admission were
recorded prospectively in each cohort, with prospective
adjudication of outcomes. A previous diagnosis of diabetes
mellitus was based on self-report by the patient, ongoing
antidiabetic therapy, or documentation in the patient’s med-
ical records. Estimated glomerular ﬁltration rate was esti-
mated by the Modiﬁed Diet in Renal Disease formula (21).
As we sought to determine both short- and long-term prog-
nosis by BMI, we excluded patients without BMI data
available on admission and without adjudication of events at
least 6 months after index admission. To adjust for possible
frailty, we excluded patients with a BMI <18.5 kg/m2 in all
analyses.All-causemortality was assessed at 30 days and 1 year
by medical chart review at each speciﬁc institution as previ-
ously described (22). Cause-speciﬁc mortality was not avail-
able in this transnational cohort. All study procedures were
approved by local institutional review boards/ethics.
Statistical analysis. Baseline demographic characteristics
were expressed as median and interquartile range or frequency,
and were compared using nonparametric techniques for
continuous data (e.g.,Wilcoxon orKruskal-Wallis test) or chi-
square testing for categorical covariates. The primary outcome
of our study was all-cause mortality at 30 days and 1 year post-
discharge for ADHF. Survival time was calculated from the
date of admission until the date of death or last follow-up.
Survival was plotted, and univariable and multivariable (co-
variate-adjusted) Cox proportional hazards regression models
were used to estimate effects for each covariate, with simul-
taneous adjustment for potential confounders in multivariable
models. Proportional hazards assumptions were veriﬁed. The
log-linearity of BMI was conﬁrmed in all patients for 30-day
and 1-year mortality. Accordingly, the main exposure was
deﬁned by a 5-kg/m2 increase in BMI (similar to the scaling
reported by prior investigators [1]).
Covariates included for adjustment inmultivariable models
were age, sex, history of prior HF, history of coronary artery
disease, atrial ﬁbrillation, diabetes mellitus, blood pressure
(systolic and diastolic), heart rate, presence of decreased
renal function (as calculated by Crockault-Gault estimated
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780glomerular ﬁltration rate <60 ml/min/1.73 m2), hypergly-
cemia (deﬁned as glucose7 mmol/l for nondiabetic subjects
and10 mmol/l for patients with prevalent diabetes mellitus
[22]) and hyponatremia (serum sodium concentration <136
mmol/l). Our study was composed of a worldwide sample of
patients with ADHF; given that patients were included from
various centers, a potential cluster effect was taken into
account using generalized linear models with a random
intercept where the cluster of interest was the country.
In addition, to assess potential effect modiﬁcation by certain
clinical factors important in the diagnosis and treatment of HF
on the association of BMI with all-cause mortality at 1 year, we
performed multivariable Cox regression models for BMI in
various subgroups relevant to ADHF prognosis, including de
novo HF (deﬁned as ADHF hospitalization without prior
clinical diagnosis of HF), age (stratiﬁed at 75 years), sex, left
ventricular ejection fraction (LVEF) (stratiﬁed at 50%), and
diabetes. We adjusted for all covariates speciﬁed in the main
multivariable Cox regressionmodel for these subgroup analyses.
Finally, we assessed risk reclassiﬁcation of BMI beyond a
clinical model (composed of all covariates listed in the main
multivariable model) using net reclassiﬁcation analysis.
Continuous net reclassiﬁcation improvement (NRI) for
BMI for the prediction of 1-year mortality was estimated by
published techniques (23).
Statistical analyses were performed using R (version
2.15.0, R Foundation for Statistical Computing, Vienna,
Austria). A 2-sided p value <0.05 was considered to be
statistically signiﬁcant.
Results
Study population. The derivation of the study population is
shown in Figure 1. Of 9,158 patients originally included in
the registry, patients were serially excluded for BMI data
unavailable (n ¼ 2,768), survival data beyond 30 days
unavailable (n ¼ 53), and BMI <18.5 kg/m2 (n ¼ 195). OurFigure 1 Derivation of the Study Population
BMI ¼ body mass index; GREAT ¼ Global Research on Acute Conditions Team;
HF ¼ heart failure.ﬁnal population thus consisted of 6,142 patients, stratiﬁed by
World Health Organization guidelines: normal weight (BMI
18.5 to 25 kg/m2; n¼ 2,197); overweight (BMI 25 to 30 kg/m2;
n ¼ 2,243), and obese (BMI 30 kg/m2; n ¼ 1,702).
Clinical, demographic, biochemical, and echocardio-
graphic characteristics of the study population. Baseline
characteristics of our intercontinental population stratiﬁed by
obesity status are shown in Table 1. As expected, relative to
overweight/obese ADHF patients, patients with normal
weight were older and had a lower prevalence of obesity-
related illness (e.g., diabetes, hypertension, and coronary
artery disease). In addition, beta-blocker use, statin use, and
renin-angiotensin system inhibition were less frequent
among normal-weight patients. On admission, patients who
were normal weight had lower systolic blood pressure and
lower sodium concentration, LVEF, and hemoglobin.
Concentrations of natriuretic peptides (B-type natriuretic
peptide, N-terminal pro–B-type natriuretic peptide, and
mid-regional pro-atrial natriuretic peptide) and serum
troponin I were lower in obese persons (Table 1). In contrast,
there were no differences in soluble ST2, C-reactive protein,
mid-regional pro-adrenomedullin, or cystatin C across BMI
categories.
Across theworld,BMIwas higher amongpatients admitted
for ADHF in Europe and the Americas as compared with
Asia. In addition, there was clinically signiﬁcant heterogeneity
across the world in sex, comorbid cardiometabolic illness (e.g.,
diabetes, hypertension, and coronary artery disease), drug
therapy for HF, biomarkers of neurohormonal activation, and
characteristics of initial presentation (Online Table 1).
Association of body mass index with short- and long-
term HF mortality. In Cox regression models for 30-day
and 1-year mortality in ADHF (Table 2), several well-
known correlates of risk in HF (e.g., age, serum sodium,
renal dysfunction, blood pressure) were associated with
outcome in our cohort. When treated as a continuous
covariate, BMI was associated with 30-day mortality (hazard
ratio [HR]: 0.89 for every 5 kg/m2 increase in BMI;
95% conﬁdence interval [CI]: 0.80 to 0.98; p ¼ 0.02) in
unadjusted, but not in a multivariable (fully adjusted) model.
Conversely, at 1 year, BMI was associated with mortality in
both unadjusted and adjusted analyses (adjusted HR: 0.91 for
every 5 kg/m2 increase in BMI; 95% CI: 0.87 to 0.96;
p < 0.001). When BMI was stratiﬁed by World Health
Organization criteria for obesity (normal 18.5 to 25 kg/m2,
overweight 25 to 30 kg/m2, obese 30 kg/m2), event-free
survival was greatest among obese subjects, followed by
overweight and normal-weight persons, both at 30 days and
at 1 year (Fig. 2). The association of greater BMI with
improved 1-year outcome was maintained after further
adjustment for B-type natriuretic peptide (HR: 0.86; 95%
CI: 0.79 to 0.94; p ¼ 0.001) and LVEF (HR: 0.89; 95%
CI: 0.83 to 0.94; p < 0.001), and both (Online Table 2).
In addition, a protective association of BMI with all-cause
mortality at 1 year remained after excluding patients with
grade 3 obesity (BMI>40 kg/m2; HR: 0.85; 95% CI: 0.79 to
Table 1 Baseline Clinical, Demographic, and Biochemical Characteristics, Stratiﬁed by Weight Status on Admission
Covariate Available
Normal Weight
BMI 18.5–25 kg/m2
(n ¼ 2,197)
Overweight
BMI 25–30 kg/m2
(n ¼ 2,243)
Obese
BMI 30þ kg/m2
(n ¼ 1,702) p Value
Demographics
Age, yrs 6,140 (>99) 76.3 (67–83) 73.8 (64.6–79.9) 69.1 (60.3–76.9) <0.001
Male 6,142 (100) 1,179 (54) 1,323 (59) 925 (54) <0.001
BMI, kg/m2 6,142 (100) 22.9 (21.3–24.1) 27.3 (26.1–28.4) 33.2 (31.2–36.3) <0.001
Diabetes mellitus 6,112 (>99) 604 (28) 883 (40) 864 (51) <0.001
COPD 5,990 (98) 355 (17) 388 (18) 320 (19) 0.09
Hypertension 5,343 (87) 1,024 (60) 1,393 (69) 1,248 (78) <0.001
History of HF 5,943 (97) 1,095 (52) 1,060 (49) 837 (50) 0.18
Atrial ﬁbrillation 5,808 (95) 681 (33) 645 (31) 491 (30) 0.12
History of CAD 6,023 (98) 962 (45) 1,164 (53) 788 (47) <0.001
Medication use at admission
Beta-blocker 5,417 (88) 884 (45) 954 (48) 742 (51) <0.01
ACE inhibitor 5,141 (84) 733 (39) 858 (46) 632 (45) <0.001
ARB 5,131 (84) 439 (24) 415 (22) 378 (27) <0.01
Diuretics 5,338 (87) 1,123 (57) 1,055 (54) 799 (56) 0.16
Nitrates 4,706 (77) 317 (21) 343 (19) 255 (19) 0.33
Aspirin 4,502 (73) 589 (41) 677 (40) 560 (42) 0.47
Statin 4,305 (70) 344 (25) 499 (30) 409 (32) <0.001
Hemodynamic and biochemical status
on admission
SBP, mm Hg 6,088 (99) 130 (110–157) 135 (115–160) 140 (120–160) <0.001
DBP, mm Hg 6,070 (99) 77 (64–90) 80 (70–90) 80 (70–95) <0.001
Heart rate, beats/min 6,075 (99) 89 (74–109) 88 (72–107) 88 (73–107) 0.11
LVEF, %* 3,157 (51) 38 (25–54) 38 (26–51) 43 (30–55) <0.001
Hemoglobin, mg/dl 5,632 (92) 12.5 (11–14) 13 (11.6–14.4) 13.1 (11.7–14.6) <0.001
Serum sodium, mEq/l 6,024 (98) 138 (136–141) 139 (136–141) 139 (136–141) <0.001
Serum potassium, mEq/l 3,217 (52) 4.1 (3.8–4.5) 4.2 (3.8–4.6) 4.2 (3.8–4.6) 0.27
eGFR, ml/min/1.73 m2 6,077 (99) 52.9 (37–71.5) 54.9 (39.7–71.8) 55.5 (40.7–73.2) <0.001
Admission glucose, mmol/l 5,217 (85) 7.5 (5.8–12.9) 7.7 (6–11.1) 7.8 (6–11.4) 0.74
Biomarkers
BNP, ng/l 2,585 (42) 1,002 (527–1,827) 885 (420–1,626) 666 (340–1,156) <0.001
MR-proADM, nmol/l 344 (6) 1.58 (1.19–2.26) 1.51 (1.05–2.35) 1.62 (1.11–2.36) 0.61
MR-proANP, pmol/l 476 (8) 470 (301.8–665) 397 (259.6–590.8) 311.5 (205.2–463.5) <0.001
NT-proBNP, ng/l 836 (14) 6,178 (2,607–13,884) 4,686 (1,991–9,490) 2,906 (1,403–5,876) <0.001
Cystatin C, mg/l 257 (4) 1.26 (0.98–1.83) 1.12 (0.91–1.49) 1.19 (0.97–1.5) 0.14
sST2, ng/ml 302 (5) 49.7 (32.6–97.5) 47.5 (30.2–85) 44.6 (32.5–78.7) 0.74
hsCRP, mg/l 1,419 (23) 10.5 (4–38) 14 (5–42) 12 (5–33.4) 0.20
Troponin I, mg/l 948 (15) 0.02 (0.005–0.1) 0.01 (0.005–0.1) 0.005 (0.005–0.05) <0.001
Values are n (%) or median (interquartile range). *Obtained during index hospitalization.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin-receptor blocker; BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive
pulmonary disease; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure; hsCRP ¼ high-sensitivity C-reactive protein; LVEF ¼ left ventricular ejection fraction;
MR-proADM ¼ mid-regional pro-adrenomedullin; MR-proANP ¼ mid-regional pro-atrial natriuretic peptide; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; SBP ¼ systolic blood pressure.
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7810.92; p < 0.001), excluding the largest referral center for our
study (Czech Republic), or accounting for a ﬁxed cluster
effect. When classiﬁed by number of cardiovascular medi-
cations used on admission (with 1 point each for beta-
blockade, angiotensin-converting enzyme inhibition,
angiotensin-II receptor blockade, statin therapy, diuretics,
and nitrates), nonobese patients (BMI <30 kg/m2) receiving
more medical therapy on admission appeared to have a better
short-term (30-day) survival relative to obese patients
(Online Fig. 1), although this result was not robust to
multivariable adjustment. Finally, in an exploratory analysis
of patients within the obese stratum (grade 1, 30 to 35 kg/m2;
grade 2, 35 to 40 kg/m2; grade 3, 40þ kg/m2), all patientsexcept those in the highest obesity stratum (grade 3) had an
equivalent or lower hazard of all-cause mortality relative to a
reference BMI 18.5 to 25 kg/m2 at 30 days and 1 year after
full adjustment; the heaviest patients had a higher 30-day
(but not 1-year) mortality. All sensitivity analyses were
adjusted for the same covariates as in the fully adjusted
multivariable model.
When comparedwith clinical risk assessments (as described
by a multivariable model including all covariates in Table 2
except BMI), BMI provided signiﬁcant reclassiﬁcation of
all-cause mortality at 1 year, with a continuous net reclassiﬁ-
cation index (NRI) of 0.119 (95% CI: 0.050 to 0.188;
p < 0.001). Importantly, risk reclassiﬁcation by BMI was
Table 2
Univariable and Multivariable Cox Regression Models for 30-Day and 1-Year Post-Discharge Mortality
Among Patients With Acute HF
Covariate
30-Day Mortality 1-Year Mortality
Univariable
HR (95% CI) p Value
Multivariable
HR (95% CI) p Value
Univariable
HR (95% CI) p Value
Multivariable
HR (95% CI) p Value
BMI, per 5 kg/m2 0.89 (0.80–0.98) 0.02 1.02 (0.92–1.12) 0.77 0.81 (0.73–0.90) <0.001 0.91 (0.87–0.96) <0.001
Diabetes mellitus 1.09 (0.82–1.45) 0.55 1.19 (0.92–1.54) 0.18 1.13 (0.90–1.42) 0.28 1.18 (0.96–1.46) 0.11
Hyperglycemia 2.15 (1.44–3.22) <0.001 1.80 (1.37–2.35) <0.001 1.27 (1.04–1.54) 0.02 1.15 (0.96–1.38) 0.12
Male 1.12 (0.86–1.45) 0.40 1.15 (0.90–1.47) 0.27 1.12 (0.93–1.35) 0.23 1.28 (1.13–1.44) <0.001
Age, for 1 yr 1.03 (1.01–1.05) 0.001 1.04 (1.02–1.05) <0.001 1.04 (1.03–1.04) <0.001 1.04 (1.03–1.04) <0.001
eGFR <60 ml/min/1.73 m2 2.36 (1.93–2.90) <0.001 1.70 (1.37–2.12) <0.001 2.33 (2.03–2.66) <0.001 1.78 (1.59–2.00) <0.001
SBP, for 1 mm Hg 0.98 (0.97–0.98) <0.001 0.98 (0.97–0.98) <0.001 0.99 (0.98–0.99) <0.001 0.99 (0.99–0.99) <0.001
DBP, for 1 mm Hg 0.97 (0.96–0.98) <0.001 1.00 (0.99–1.01) 0.47 0.98 (0.97–0.98) <0.001 0.99 (0.99–1.00) 0.02
Heart rate, per beat/min 1.00 (0.99–1.00) 0.75 1.00 (1.00–1.01) 0.33 1.00 (1.00–1.00) 0.07 1.00 (1.00–1.00) 0.15
Sodium <136 mmol/l 2.24 (1.71–2.94) <0.001 1.74 (1.32–2.28) <0.001 1.91 (1.63–2.23) <0.001 1.56 (1.32–1.84) <0.001
History of HF 0.70 (0.41–1.19) 0.19 0.58 (0.43–0.79) <0.001 1.25 (0.93–1.68) 0.14 0.97 (0.81–1.16) 0.75
CAD 1.68 (1.18–2.38) 0.004 1.30 (0.95–1.77) 0.10 1.42 (1.25–1.61) <0.001 1.15 (0.97–1.37) 0.12
Atrial ﬁbrillation 0.78 (0.56–1.08) 0.14 0.82 (0.70–0.97) 0.02 1.15 (1.00–1.33) 0.05 0.99 (0.96–1.02) 0.48
A total of 4,917 patients were included in fully adjusted multivariable models.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
Figure 2
All-Cause Mortality 30 Days and 1 Year
After Discharge
All-cause mortality to (top) 30 days post-discharge and (bottom) 1-year
post-discharge after index hospitalization. Both survival curves are signiﬁcant
(p < 0.001). Solid line indicates body mass index (BMI) 18.5 to 25 kg/m2;
dashed line indicates BMI 25 to 30 kg/m2; dotted line indicates BMI >30 kg/m2.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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782more prominent among patients who died (NRI for events:
0.190) relative to patients who remained alive during follow-
up (NRI for nonevents: 0.07).
Obesity paradox is a global phenomenon and is conﬁned
to select subgroups within HF. The association of higher
BMI with lower all-cause mortality persisted across the
world in Asia (104 events, HR: 0.53; 95% CI: 0.39 to
0.72), Western Europe (520 events, HR: 0.71; 95% CI:
0.64 to 0.78), Central Europe (481 events, HR: 0.80; 95%
CI: 0.74 to 0.87), and North America (125 events, HR:
0.85; 95% CI: 0.76 to 0.94); although comparable direc-
tional trends existed relative to outcomes of patients in
South America (39 events, HR: 0.90; 95% CI: 0.63 to
1.28), the result was not statistically signiﬁcant, likely
limited by a reduced number of mortality events on this
continent (Fig. 3).
Although a higher BMI was associated with generally
favorable 1-year prognosis across the groups examined with
comparable directional trends, heterogeneity existed when
examined as a function of age, diabetes, and LVEF, with a
higher BMI particularly associated with lower mortality
among older persons (age>75 years, HR: 0.82; 95%CI: 0.72
to 0.95; p ¼ 0.006), those with reduced ejection fraction
(LVEF <50%, HR: 0.85; 95% CI: 0.79 to 0.92; p < 0.001),
and those without diabetes mellitus (HR: 0.86; 95% CI: 0.79
to 0.93; p < 0.001). In addition, the protective association of
BMI with all-cause mortality was present in patients with
de novoHF (diagnosed on admission)dbut not patients with
established chronic HF admitted with acute decompensation.
As expected, there were signiﬁcant differences between
patients with de novo HF and established ADHF, though
BMI was not signiﬁcantly different (Online Table 3). All
subgroup analyses were fully adjusted using the same cova-
riates as in the main multivariable model.
Figure 3 Forest Plot of HR for Association of BMI With All-Cause Mortality
Forest plot of HRs for association of BMI, per 5 kg/m2 increments, with all-cause mortality by Cox regression. Each stratum-speciﬁc hazard ratio was adjusted for all covariates
speciﬁed in Table 2. pinteract represents the p value for the HR representing an interaction between each covariate and BMI. ADHF ¼ acute decompensated heart failure; LVEF ¼
left ventricular ejection fraction; other abbreviations as in Figures 1 and 2.
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Obesity is a global epidemic strongly associated with the
development of a broad array of cardiovascular diseases.
International clinical practice guidelines increasingly call for
antiobesity efforts with the goal to prevent incident cardio-
vascular and metabolic disease. However, amidst this
worldwide mandate for weight loss, an “obesity paradox” has
been noted with a variety of cardiovascular ailments, wherein
a higher BMI has been reported as “protective” against
cardiovascular events, including HF (24). This observation
has led to signiﬁcant controversy as to the demerits of
obesity once cardiovascular disease is established (9).
This special cohort provides a unique opportunity to
examine ADHF prognosis and its determinants across con-
tinents, which allows us to reﬁne an obesity paradox in HF
across multiple geographic regions. We provide evidence for
the existence of a global obesity paradox in ADHF, with a
higher BMI associated with improved 30-day and
1-year mortality worldwide despite intercontinental hetero-
geneity in clinical and biochemical admission proﬁles, sug-
gesting that an association between mortality and BMI is
robust. In fully adjusted models, BMI was associated with all-
cause mortality at 1 year but not at 30 days, suggesting that
BMI may be a more speciﬁc marker of longer-term outcome.
We demonstrate further that the association of BMI with
outcome is speciﬁc to selected subgroups (nondiabetic per-
sons, de novo HF diagnosis, older age, HF with reduced
LVEF), suggesting a level of complexity beyond a simple
protective effect of higher weights across all patients with HF.
Finally, we demonstrate that a lower BMI effectively reclas-
siﬁes the risk of long-term mortality beyond clinical indexes,
suggesting an important opportunity to identify low BMIpersons at high clinical risk for potential nutritional
interventions.
Although an obesity paradox does not seem to be present in
extreme obesity (25), explanations for the link between higher
BMI and survival in HF remain speculative. Excess adiposity
may putatively reﬂect a metabolic sink capable of resisting
catabolic demands inHF (26–28). Indeed, a 6%weight loss in
patients with advanced chronic HF is associated with a more
than 2-fold increased risk of death (29). This nutritional
hypothesis appears speciﬁcally important for older adults: in a
study of 244 patients (mean age 83 years), obese persons with
chronic HF were older, with greater absolute lymphocyte
count and serum albumin level relative to normal-weight
older HF patients, suggesting that BMI and nutritional
status may be collinear in an older age range (30), a theory
supported by our ﬁndings of higher risk particularly among
older patients with lower body weight. Lower BMI in chronic
HF is associated with negative energy balance inHF, systemic
inﬂammation/catabolism (e.g., tumor necrosis factor-alpha,
catecholamine, and glucocorticoid excess), decreased lean
and fat mass, and poorer prognosis independent of age,
functional status, left ventricular (LV) function, and aerobic
capacity (31). Higher tumor necrosis factor-alpha, insulin
resistance, and catecholamine excess are linked to cachexia in
chronic HF with reduced LV function (32). Moreover,
increased adiposity in rodent studies may defend mitochon-
drial function during pressure-overload (reduced LV func-
tion) HF (33), suggesting that BMI not only reﬂects cachexia
and ambient inﬂammation, but also may be a marker of
improved mitochondrial function in HF. Indeed, obesity in
HF with reduced ejection fraction reﬂects both more lean
muscle mass (associated with overall strength) and greater
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784adiposity, associated with improvements in strength and
exercise capacity (34). Ultimately, frailty leads to increased
hospitalization and cost in HF (35). Indeed, in an analysis
including the 195 patients in our cohort with “cachexia”
(as deﬁned by BMI <18.5 kg/m2), cachectic patients had a
markedly increased hazard of death relative to other BMI
categories (Online Fig. 2).
Although exercise- and dietary-mediated weight loss of
obese persons with HF (speciﬁcally with normal LV func-
tion) remains supported by practice guidelines (36), our
results suggest closer clinical surveillance for patients with
unintentional weight loss who are hospitalized with HF.
Although in aggregate our ﬁndings in ADHF agree with
prior reports regarding chronic HF attesting to a protection
from death with a higher BMI, our data suggest that the
prognostic association of BMI with mortality is more
complex than previously articulated, depending on age, LV
function, and chronicity of HF, issues at the heart of ADHF
risk stratiﬁcation and management. Ultimately, the clinical
implications of BMI are not region speciﬁc, but are speciﬁc
to patient characteristics, severity, and type of HF. This
insight also mandates that ongoing efforts in ADHF
investigation consider differences in mortality by BMI cat-
egories, speciﬁcally as they interact with age, LV function,
and chronicity. Failure to consider these emerging concepts
in clinical trials design may lead to decreased event rates and
underpowered, nongeneralizable results. In this context, we
established that certain prognostic HF markers (e.g., ST2)
are not affected by BMI, suggesting their centrality for
clinical and research use in ADHF, independent of BMI.
Study limitations. The conclusions of our study should be
viewed in the context of its design. Although every patient in
this study has ADHF, the details of symptomatic status
before admission (e.g., New York Heart Association func-
tional class) and pre-hospital course are not speciﬁed. In
addition, although weight assessed on admission may reﬂect
some component of ﬂuid overload, increased ﬂuid (a higher
BMI referable to more “HF”) would be expected to worsen
mortality (not improvemortality, as we observed in this study).
Although patients without BMI data available (Fig. 1) were
excluded, the remaining population was a large, multinational
cohortwith robust association betweenBMI and prognosis. In
addition, the sample population was derived from a collection
of prospectively enrolled studies of ADHF worldwide, and as
such, data collection for certainmarkers of HF disease severity
(e.g., echocardiography) was not uniform across continents.
However, the strength of intercontinental patient recruit-
ment, full adjudication of clinical outcome, and complete
assessment of known clinical, hemodynamic, and biomarkers
of prognosis increase the generalizability of our results. In
addition, although we did not have data on speciﬁc cause of
mortality in these persons, patients with active conditions
limiting survival were excluded from the population. We did
not have data regarding in-hospital management across
different continents in this study; however, the lack of effect
modiﬁcation of location with the association between BMIand mortality suggests that the site-speciﬁc treatment differ-
ences may not greatly affect the strength of this relationship.
Finally, given the lack of data on longitudinal changes inweight
over time, associations among weight change (intentional or
unintentional), BMI, and outcome could not be assessed.
Conclusions
Although these observations certainly do not endorse weight
gain to “protect” patients with established HF, the general
implication is that a lower BMI in ADHF identiﬁes patients
at particularly high risk. This phenomenon is evident in
patients previously classiﬁed as “normal weight,” thereby
possibly resetting what is considered the lower normative
bound for BMI in the ADHF setting. Ultimately, whereas a
high BMI may not be the arbiter of prognostic beneﬁt for
patients hospitalized with HF, a normal BMIdespecially in
the context of cardiac function and older agedparticularly
signals adverse long-term prognosis. The clinical manage-
ment of excess weight in patients hospitalized for ADHF
needs speciﬁc tailoring at this sentinel stage in disease
progression.
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